EGFR and non-small cell lung carcinoma: Overall, our findings highlight the multifactorial nature of prognosis in EGFR-mutant NSCLC, supporting a comprehensive approach that incorporates molecular, clinical, and functional parameters to predict patient outcomes and inform treatment plans.